X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

Shimadzu’s Nexera XS Inert Chromatography System Enhances Biopharma Analysis

Content Team by Content Team
28th July 2022
in IPR Data Management, Press Statements
Shimadzu's Nexera XS Inert Chromatography System Enhances Biopharma Analysis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Shimadzu’s new ultra-high performance liquid chromatography system is designed to solve common problems in biopharma analysis.

Shimadzu launched its new Nexera XS inert, a bioinert and biocompatible ultra-high performance liquid chromatograph (UHPLC), in July 2022. The system is designed to resolve the most common problems in biopharmaceutical analysis, such as the adsorption of target molecules to metal surfaces and mobile-phase corrosion caused by high salt content and extreme pH conditions.

The Nexera XS inert UHPLC resulted from cooperative research done with Yasushi Ishihama, a professor at the Graduate School of Pharmaceutical Sciences at Kyoto University in Japan under the Japan Science and Technology Agency’s Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) project from 2017 to 2020. The system features a metal-free sample flow path, which prevents unwanted interaction with biopolymers that are prone to adsorption onto exposed metal sites. Through this mechanism, the Nexera XS inert results in reduced sample loss and excellent peak shape for generating reproducible, high-sensitivity and high-quality reliable data, according to a July 19, 2022 company press release.

Furthermore, all wetted surfaces have been prepared from corrosion-resistant materials, which renders them stable against mobile-phase solvents that contain high concentrations of salts or acids. Nexera XS inert is particularly well-suited for analyzing biopharmaceutical molecules, such as antibodies, peptides, and nucleic acid drugs.

The new system offers the same analytical intelligence features as the other products in the Nexera series as well as the following features:

  • Unconstrained recovery and sensitivity: in the quantitative analysis of biomolecules, adsorption of the target compound to a metal surface can result in a dramatic decrease in sensitivity. The Nexera XS inert system comprises stainless-steel-casing-reinforced polyether ether ketone (PEEK) tubing, which is a high-performance engineered polymer with mechanical- and chemical-resistance properties. This ensures a system pressure tolerance of > 100 MPa while maintaining a bioinert flow path. The system also includes a ceramic injection needle, which offers metal-free injections and minimized carryover. By preventing adsorption to metal surfaces, the Nexera XS inert system thus achieves much higher sensitivity and better reproducibility than a general-purpose UHPLC system.
  • Assured reliability and reproducibility: high salt conditions in the mobile phase can result in the corrosion of stainless-steel parts in standard UHPLC systems, but, in the Nexera XS inert system, the wetted surfaces are prepared from highly rust-resistant materials, while still maintaining the high-efficiency flow-path (i.e., 105 MPa). Because of this design, the system remains unaffected by high salt content, ion pairing agents, or extreme pH conditions, ensuring long-term stability and reliable data acquisition.
  • Clear resolution without restrictions: the system’s ability to resist 105 MPa of pressure means it can use long separation columns packed with small-sized particles, which allows it to achieve ultra-high efficiency in a wide variety of applications. The newly developed PEEK-lined tubing comes with tool-free, finger-tightened fittings, allowing for reliable connections between columns, which enables the system to withstand a pressure of up to 105 MPa without creating any dead volume or risking damage by overtightening. All valves used in the Nexera XS inert system have been designed to inhibit metal adsorption for worry-free switching between multiple columns. This characteristic is useful for method development or for trap-and-elute analysis. An optional pHM-40 offers real-time measurement of the mobile-phase pH during the course of an experiment. This ensures accuracy and traceability, even when running a pH gradient, as used in ion exchange chromatography.
  • Consumables ideal for analyzing biopharmaceuticals: analyzing biomolecules, such as proteins, peptides and nucleic acids, requires columns with different separation modes. For some samples that are sensitive to metal ions, metal adsorption must be taken into consideration, and an optimal column would address this issue. The columns used in this new system (Shim-pack series of columns) is fitting for the analysis of a wide variety of biomolecules. In addition, adsorption of target analytes in the sample vial can greatly affect the analysis and requires special attention. Furthermore, a low-adsorption polypropylene vial (TORAST-H Bio Vial, Shimadzu) is also most fitting for peptide drug research, while low-adsorption glass vials (TORAST-H, Shimadzu) are suitable for general-purpose analysis.
Previous Post

Roche Launches Dual Antigen and Antibody Hepatitis C Diagnostic Test

Next Post

GSK To Aid 12 European Countries Prepare For Future Pandemic

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Pharma Advancement Banner
Press Statements

Welcome to the Inaugural Operationalize: Expanded Access Programs Summit West

27th June 2025
Next Post
GSK Unveils Its Transformation Through New Branding And Logo

GSK To Aid 12 European Countries Prepare For Future Pandemic

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In